Ibrutinib, a covalent inhibitor of Bruton Tyrosine Kinase (BTK), is approved for treatment of patients with relapsed/refractory or treatment-naïve chronic lymphocytic leukemia (CLL). Besides directly inhibiting BTK, ibrutinib possesses immunomodulatory properties through targeting multiple signaling pathways. Understanding how this ancillary property of ibrutinib modifies the CLL microenvironment is crucial for further exploration of immune responses in this disease and devising future combination therapies. Here, we investigated the mechanisms underlying the immunomodulatory properties of ibrutinib. In peripheral blood samples collected prospectively from CLL patients treated with ibrutinib monotherapy, we observed selective and durable downregulation of PD-L1 on CLL cells by 3 months post-treatment. Further analysis showed that this effect was mediated through inhibition of the constitutively active signal transducer and activator of transcription 3 (STAT3) in CLL cells. Similar downregulation of PD-1 was observed in CD4+ and CD8+ T cells. We also demonstrated reduced interleukin (IL)-10 production by CLL cells in patients receiving ibrutinib, which was also linked to suppression of STAT3 phosphorylation. Taken together, these findings provide a mechanistic basis for immunomodulation by ibrutinib through inhibition of the STAT3 pathway, critical in inducing and sustaining tumor immune tolerance. The data also merit testing of combination treatments combining ibrutinib with agents capable of augmenting its immunomodulatory effects.
INTRODUCTION
Chronic lymphocytic leukemia (CLL) is characterized by profound immunosuppression that involves multiple T-cell defects. These include an exhausted T-cell phenotype marked by profound impairment in proliferation and function, 1,2 disruption of immune synapse formation, 3 an increase in CD4 + CD25 hi regulatory T cells 4, 5 and upregulation of checkpoint molecules such as programmed death-1 (PD-1). 6, 7 CLL cells can directly interfere with normal T-cell function through several different mechanisms, including secretion of the immunosuppressive cytokine IL-10, a feature shared with the recently described regulatory B10 cells, [8] [9] [10] [11] as well as aberrant expression of several inhibitory receptors, notably, programmed death ligand-1 (PD-L1). 12 Even untreated, early stage CLL or its precursor condition, monoclonal B-cell lymphocytosis, are associated with significant infection risk, 13, 14 a leading cause of morbidity and mortality in this disease.
Bruton Tyrosine Kinase (BTK), a member of the TEC tyrosine kinase family, is a key enzyme in the B-cell receptor signaling pathway and plays an important role in the activation and survival of B cells. As such, it is a unique therapeutic target in B-cell malignancies. [15] [16] [17] [18] [19] [20] BTK also controls multiple downstream signaling pathways, 21 including the signal transducer and activator of transcription 3 (STAT3), a transcription factor involved not only in the pathogenesis and persistence of CLL 22, 23 but also in inducing and sustaining tumor immune tolerance. 24, 25 Ibrutinib is a potent covalent inhibitor of BTK 26 and is highly effective therapy for CLL. In this study, we present evidence that in addition to its direct antitumor effect via targeting of BTK, ibrutinib modulates the immunosuppressive CLL microenvironment through inhibition of the STAT3 pathway. By suppressing STAT3, the drug inhibits CLL B10 function and induces downregulation of PD-1/PD-L1 expression, potentially enhancing antitumor immune responses.
MATERIALS AND METHODS Patients
Clinical samples from 17 consecutive patients with relapsed or refractory CLL, enrolled in an investigator-initiated trial of ibrutinib alone (420 mg once daily until disease progression or the development of unacceptable toxicity; NCT02007044) and from control patients treated with chlorambucil monotherapy (NCT01722487 and Chronic Lymphocytic Leukemia Research Consortium, University of California, San Diego) were studied with approval of the local institutional review board and in accordance with the Declaration of Helsinki. Patient characteristics are summarized in Table 1 . The median age was 68 years (range 55-79 years). Most (71%) had 1 advanced stage disease (Rai stage III or IV); 47% had bulky lymph nodes (⩾5 cm) and the median number of prior treatment regimens received was 1.5 (range, 0-6). Peripheral blood was collected before (Pre-dose), and at 3 and 6 months after the initiation of ibrutinib therapy. Peripheral blood mononuclear cells (PBMCs) were isolated by density-gradient-separation (Lymphoprep), cryopreserved in 90% fetal bovine serum/10% dimethyl sulfoxide and stored in liquid nitrogen. In addition, lymphocytes from 11 normal donors were analyzed.
Reagents
Ibrutinib (PCI-32765) was purchased from Selleck Chemicals (Houston, TX, USA) and added to the assay medium to a final concentration of 1 μM. Details of monoclonal antibodies are included in the Supplementary Material.
Immunofluorescence staining and flow cytometric analysis For surface staining, PBMCs were washed with staining buffer (phosphatebuffered saline containing 2% fetal calf serum), incubated with directly conjugated mAbs and Live/Dead Aqua for 405 nm excitation (Life Technologies, Carlsbad, CA, USA) for 20 min at room temperature in the dark and then washed and resuspended in 4% paraformaldehyde/ phosphate-buffered saline solution. Flow cytometry was performed on a BD Fortessa flow cytometer followed by analysis with FlowJo Version 10.0.8 software (TreeStar, Ashland, OR, USA), after gating on live singlet cells. The gating strategy for flow analysis is presented in Supplementary Figure S1 .
Phosflow assay
Cells were stained with Live/Dead Aqua (Life Technologies), CD19-V450 (BD, San Jose, CA, USA) and CD5-FITC (BioLegend, San Diego, CA, USA) Abs for 20 min, washed, fixed/permeabilized (PerFix EXPOSE; Beckman Coulter, Brea, CA, USA) and stained with the p-S727-STAT3-PE mAb (BD Biosciences, San Jose, CA, USA) for 30 min at room temperature.
BCR and CD40 ligation
Cells were stimulated with either goat anti-human IgM+IgG (20 μg/ml; Jackson ImmunoResearch, West Grove, PA, USA) or with soluble CD40L (100 ng/ml; Adipogen, San Diego, CA, USA) for 20 min at 37°C. Cells were then fixed, permeabilized and stained with the p-S727-STAT3-PE antibody as described above.
Coculture experiments with STAT3 inhibitor or ibrutinib
PBMCs from CLL patients were cultured for 24 or 48 h at 37 o C in SCGM medium (Cell Genix, Freiburg im Breisgau, Germany) in the presence or absence of the STAT3 inhibitor cucurbitacin (0.05 μM) or ibrutinib (1 μM; Selleck Chemicals). Cells were stained for 30 min with mAbs against PD-L1, CD3, CD4, CD8, CD19, CD5 and Live/Dead Aqua (Invitrogen, Carlsbad, CA, USA) to check viability. Cells were also stained for p-S727-STAT3 by phosflow as described above.
Intracellular cytokine staining to detect IL-10 production by CLL cells Cryopreserved PBMCs from CLL patients collected before, and 3 and 6 months after ibrutinib therapy were thawed and stimulated with CpG (4 μg/ml; Hycult Biotech, Uden, Netherland) plus CD40L (100 ng/ml) for 10 h. In another experiment, PBMCs from untreated CLL patients were cultured with ibrutinib (1 μM) or the STAT3 inhibitor cucurbitacin overnight (0.05 μM) and stimulated with CpG and CD40L for 10 h. Phorbol-myristate acetate (50 ng/ml; Sigma-Aldrich, St Louis, MO, USA), ionomycin (250 ng/ ml; Sigma-Aldrich) and brefeldin A (10 μg/ml) were added for the last 6 h of the culture. Cells were then washed and incubated for 20 min with anti-CD19-PE-cy7, CD5-FITC (BioLegend) and Live/Dead Aqua (Life Technologies). Cells were then washed and fixed/permeabilized for 1 h at 4°C using a Foxp3 staining buffer set (eBioscience, Thermo Fisher Scientific, Carlsbad, CA, USA). Cells were incubated for 30 min at room temperature with APCconjugated IL-10 or IgG2aΚ isotype antibodies (BD). All data were acquired with BD Fortessa (BD Biosciences) and analyzed with FlowJo software (Treestar). Generation of green fluorescence protein (GFP)-lentiviral-STAT3-shRNA for transfection of primary CLL cells 293T cells were co-transfected with GFP-lentivirus STAT3 short hairpin RNA (shRNA) or GFP-lentivirus empty vector and the packaging vectors pCMVdeltaR8.2 and pMDG, using the Superfect transfection reagent (Qiagen, Inc., Hilden, Germany). 293T cell culture medium was changed after 16 h and collected after 48 h. The culture medium was filtered through a 45 μM syringe filter to remove floating cells. The lentivirus was then concentrated by filtration through an Amicon ultracentrifugal filter device (Millipore, Billerica, MA, USA), and the concentrated supernatant was used to infect CLL cells. CLL cells from three different patients (5 × 10 6 / ml) were incubated in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum and transfected with viral supernatant as described. 27 
BTK knockout cell lines
The CRISPR-CAS9 system was used to knockout BTK in the RCH-ACV B-cell leukemia cell line as previously described. 28 Briefly, px458-based constructs or the empty px458 vector (control) were introduced into RCH-ACV cells by electroporation with the NEON transfection system. Viable GFP+ cells were sort-purified 72 h later on the FACSAria Fusion Sorter (BD Biosciences) and used for further experiments. Single GFP+ cells were sorted into 96-well plates to obtain single cell clones. BTK knockout was confirmed by western blot analysis. 28 
Western blotting
PBMCs collected from CLL patient pre, and at 3 and 6 months post ibrutinib therapy were lysed using 1 × Pierce IP Lysis Buffer together with 1 × Halt Protease and Phosphatase Inhibitor Cocktail (Thermo Fisher Scientific). Proteins (20 μg) were loaded on NuPAGE 4-12% Bis-Tris Protein gel and separated using NuPAGE MOPS SDS running buffer (Thermo Fisher Scientific). Proteins were transferred to a nitrocellulose membrane in NuPAGE Transfer Buffer plus 10% methanol. We used mouse anti-human monoclonal antibodies against STAT3 and β-actin, monoclonal anti-human extracellular PD-L1 and polyclonal rabbit anti-human p-S727-STAT3 (Cell Signaling, Danvers, MA, USA). IRDye 680RD goat anti-mouse and 800CW goat anti-rabbit antibodies (Li-Cor, Lincoln, NE, USA) were used as secondary antibodies. Blots were visualized using Odyssey Imaging System. Densitometry values were normalized using the values of the loading control (untreated CLL actin levels were used as reference). The numerical value for the signal of p-S727-STAT3 from each sample was divided by the numerical value of the signal from the corresponding total STAT3.
Statistical analysis
All values in statistical comparisons are means and standard errors of the mean (s.e.m.). Statistical significance was assessed with Prism 6 (GraphPad Software, Inc., La Jolla, CA, USA) and SPSS version 23 (IBM Corp., Armonk, NY, USA) using a paired two-tailed t-test for normally distributed variables, the Mann-Whitney U-test for non-normally distributed variables and ANOVA for comparison of multiple variables. P-values of ⩽ 0.05 were considered significant. In analyses with missing data, only measurements representing paired samples from individual patients were included.
RESULTS

Ibrutinib selectively modulates PD-L1 and PD-1 expression
The PD-1/PD-L1 axis is an important contributor to the dysfunctional interactions between leukemic CLL cells and host T lymphocytes.
6,7 Thus, we measured expression levels of PD-1 and other checkpoint molecules on T cells before and during ibrutinib therapy. Consistent with previous reports, 6,7 expression of inhibitory immune checkpoint molecules was significantly higher on T cells from CLL patients, compared with healthy controls (Supplementary Figure S2) . We found no significant correlation between expression levels of PD-1 on CD4+ or CD8+ T cells prior to therapy and the following parameters: number of prior therapies, previous fludarabine therapy, maximum lymph node size ⩾ 5.0 cm, β 2 -microglobulin ⩾ mg/l, presence of del(17p), IGHV somatic hypermutation status, ZAP70 expression or advanced Rai stage (data not shown).
Ibrutinib therapy resulted in a significant reduction in the frequency and absolute number of PD-1-expressing T cells by 3 months after treatment that was largely sustained at 6 months. Notably, the reduction in PD-1-expression at 3 months was significant for both CD8+ T cells (22.6 ± 1.9% pre-dose vs 16.3 ± 2.4% at 3 months, P = 0.001) and CD4+ T cells (33.2 ± 4.3% pre-dose vs 28.7 ± 4.0% at 3 months, P = 0.023) (Figure 1a) . We next asked if ibrutinib could modulate the expression of other checkpoint molecules on T cells. As shown in Figure 1b there was no evidence to support downregulation of 2B4, CD160, ICOS, OX40, Tim-3 and CTLA-4 on CD8+ or CD4+ T cells post ibrutinib therapy.
We also measured PD-L1 expression on CLL cells. Within 3 months of therapy, there was a significant downregulation of PD-L1 (mean 18.5 ± 3.06% vs 13.99 ± 3.28%, P = 0.011) by CD19+ CLL cells, which remained stable at 6 months ( Figure 1c and Supplementary Figure S3 ). Based on emerging data indicating that in cancer cells PD-1 can promote tumor growth, 29 we also measured PD-1 levels in CD19+ CLL cells. PD-1 was expressed at high levels on CLL cells, with significant downregulation after 3 months of ibrutinib therapy that persisted through 6 months ( Figure 1c ). These effects were not observed in patients treated with chlorambucil monotherapy (Supplementary Figure S4a) .
Hence, we suggest that ibrutinib selectively downregulates the expression of PD-L1 and PD-1 in the CLL microenvironment, potentially resulting in beneficial anti-pathogen and antitumor immunity. The relevance of the effect on PD-1 levels in CLL cells is unclear, but may reflect a function that is independent of adaptive immunity.
STAT3 plays an important role in the regulation of PD-L1 expression The STAT3 signaling pathway has been shown to regulate expression of PD-L1 in antigen-presenting cells as well as in a number of tumor cells, including lung cancer and T-cell lymphoma. [30] [31] [32] STAT3 is constitutively active in CLL; 23 however, it is not known if STAT3 also plays a role in the regulation of PD-L1 expression in this disease. In order to establish a direct effect of STAT3 on the expression levels of PD-L1 in CLL cells, we used a GFP lentiviral-STAT3-shRNA vector to knockdown STAT3 expression (n = 3). A mock lentiviral vector with GFP alone was used as control (n = 3). The efficiency of STAT3 knockdown in CLL cells, as measured by GFP expression, was 21% (18.5-21.5%). To study the impact of STAT3 knockdown on expression of PD-L1 in the gated GFP+ subsets, cells were stained with Dead/Live Aqua, CD3, CD19, CD5 and PD-L1 monoclonal antibodies 48 h after treatment with GFP lentiviral-STAT3-shRNA vector or a mock GFP lentiviral vector. As displayed in Figure 2 , STAT3-shRNA knockdown resulted in significant downregulation of PD-L1 in GFP+CD19+CD5+ CLL cells compared with their mock-transfected counterpart (P = 0.0001).
Ibrutinib has been reported to inhibit STAT3 activation in a number of cancer cells including gastric cancer, diffuse large B-cell lymphoma and ovarian cancer. [33] [34] [35] Thus, we asked if treatment with ibrutinib can also suppress STAT3 phosphorylation in CLL cells and downregulate PD-L1 expression. We cocultured CLL cells from treatment-naïve patients (n = 6), with ibrutinib or a STAT3 inhibitor with activity against the S727 residue (cucurbitacin) 36 and measured levels of S727-STAT3 phosphorylation and PD-L1 expression in CLL cells. Cucurbitacin is a highly selective inhibitor of STAT3 signaling, with no significant effect on other pro-survival pathways within malignant cells, such as Ras-raf-MEK-ERK and PI3k/Akt. 37 As shown in Figures 2b and 3a , treatment with either agent led to decreased expression PD-L1 and p-S727-STAT3 in CLL cells compared with findings in untreated CLL cells. To confirm these in vitro data, we also measured the constitutive levels of S727-STAT3 phosphorylation in PBMC samples collected from patients pre-dose (n = 7) and after 3 (n = 6) and 6 months (n = 5) of ibrutinib therapy. As previously reported, 7,27 S727-STAT3 was constitutively phosphorylated in all patients studied before ibrutinib treatment. Subsequently, there was a significant reduction in p-S727-STAT3 levels at 3 and 6 months compared with baseline (mean fluorescence intensity 493 ± 248 pre-dose vs 241 ± 91 at 3 months (P = 0.02) and 233 ± 86 at 6 months (P = 0.03)) (Figure 3b and Supplementary Figure S3) . A representative Phosflow plot depicting reduction in the p-STAT3 level during ibrutinib therapy is presented in Figure 3c . Taken together, these data support an inhibitory effect of ibrutinib on the STAT3 pathway.
Ibrutinib suppresses CLL B10 function by inhibiting STAT3 activation A subset of regulatory B cells, known as B10 cells, suppress effector T-cell function through STAT3-mediated production of IL-10.
8,10,38 B cells from CLL patients were recently reported to have the ability to secrete IL-10 and to perform regulatory functions comparable to those of normal B10 cells. 10, 11 This led us to investigate whether ibrutinib could also modify B10 function in CLL through suppression of STAT3. Thus, we cultured B cells from six ibrutinib-naïve CLL patients in the presence or absence of ibrutinib (1 μM) for 24 h and stimulated them with CpG (4 μg/ml) plus CD40L (100 ng/ml) to assess their ability to produce IL-10. Consistent with previous reports, 10 B cells from CLL patients produced significantly more IL-10 than B cells from healthy donors, as measured by intracellular IL-10 staining (mean 11.4 ± 2.7% vs 4.5 ± 1.1%, P = 0.047) (Figure 4a ). To address the central issue of whether ibrutinib modulates B10 function in CLL, we measured IL-10 production directly ex vivo in PBMC samples collected longitudinally from six patients before and at 3 and 6 months of ibrutinib therapy. The frequencies of CD19+IL-10+ B cells were significantly lower in the peripheral blood of CLL patients at 3 and 6 months of ibrutinib therapy, compared with pre-dose (mean 11.4 ± 2.7% at pre-dose vs 3.0 ± 0.8% at 3 months vs 1.6 ± 0.2% at 6 months, P = 0.025 and P = 0.039, respectively; Figure 4b and Supplementary Figure S5 for IL-10 secretion by ELISA). This outcome was associated with a significant reduction in constitutive levels of phosphorylated S727-STAT3 after ibrutinib therapy compared with baseline (Figures 3b and c) . In contrast, chlorambucil therapy had no impact on levels of S727-STAT3 phosphorylation in CLL Figure S6) . Considered together, our data suggest that ibrutinib modifies the ability of CLL cells to produce IL-10 and modulates the immune response by inhibiting STAT3 phosphorylation.
BTK is an upstream activator of p-S727-STAT3
A number of studies have shown that BCR or CD40 signaling can effectively activate BTK. 20, 39 Here, we showed that both pathways can also efficiently activate STAT3 (Figure 5a ). To determine if ibrutinib can modulate BCR-or CD40L-induced p-S727-STAT3 levels, we cultured CLL cells from ibrutinib-naïve patients in the presence or absence of ibrutinib (1 μM) for 24 h and measured p-S727-STAT3 levels in response to 20 min of stimulation with anti-human IgM/IgG to activate BCR or CD40L to activate the CD40/CD40L axis (Figure 5a ). The addition of ibrutinib to the culture significantly reduced anti-IgM/IgG or CD40L-induced STAT3 phosphorylation. Of note, culture of CLL cells with ibrutinib did not have a significant impact on their viability (Supplementary Figure S6) . To establish a direct relationship between BTK and p-S727-STAT3, we examined the levels of p-S727-STAT3 in a BTK knockout B-cell leukemia line in comparison with the control cell line transfected with an empty vector (BTK knockout efficiency is presented in Supplementary Figure S7) . BTK knockout significantly decreased the constitutive levels of p-S727-STAT3 (2144 ± 264 vs 1107 ± 89, P = 0.008) (Figure 5b ). We next stimulated the BTK knockout and control cell lines with CD40L. BTK knockout significantly reduced the phosphorylation of STAT3 in response to CD40L (Figure 5c ). We thus conclude that BTK signaling is upstream of STAT3 and can modulate phosphorylation of the S727 residue.
In vivo infection data and correlation with immunologic parameters At a median follow-up of 17.6 months (range 8-31), 4/17 patients (24%) experienced grade ⩾ 2 infection: grade 4 cryptococcal meningitis in 1, grade 3 pneumonia in 1 and grade 2 upper respiratory tract infections in 2 patients (Table 1) . Pre-treatment IgG levels (P = 0.002) and pre-treatment PD-1 expression on CD4+ T cells (P = 0.045) were both significantly associated with increased incidence of infection (Table 1) . Number of events was too small to perform multivariable analysis. There was no correlation between pre-treatment IgG levels and PD-1 expression on CD4+ T cells. Notably, there was no association between absolute levels of CD4 + or CD8+ T cells and infection risk, nor was there an association between IgA or IgM levels and infection risk. There was no association between PD-1 expression on CD8+ T cells and infection. The patient who developed cryptococcal meningitis Figure 4 . IL-10 production in CLL cells is reduced after ibrutinib therapy. (a) PBMCs from CLL vs healthy donors were stimulated with CpG (4 μg/ml) plus CD40L (100 ng/ml) for 12 h followed by phorbol-myristate acetate, ionomycin and brefeldin A for the last 6 h of culture and then stained for CD19 and intracellular IL-10 production. Frequencies of IL-10+CD19+ B cells are greater in CLL patients compared with healthy donors (n = 6 each) are shown. (b) PBMCs from patients given ibrutinib therapy were stimulated with CpG plus CD40L, followed by analysis of IL-10 secretion as described above (n = 7). Representative FACS plots are shown. (c) PBMCs from treatment-naïve CLL patients were cultured with ibrutinib (1 μM) or cucurbitacin (0.05 μM) overnight, and their IL-10 response to stimulation with CpG and CD40L was measured by intracellular cytokine staining (n = 6). (d) CLL cells from treatment-naïve patients were treated with a GFP lentiviral hSTAT3 shRNA vector or a mock GFP lentiviral vector as described in Materials and methods. Cells were then stimulated with 4 μM CpG and CD40L (100 ng/ml), followed by analysis for IL-10 production. IL-10 production was compared in gated CD19+GFP+ cells in transfected vs mock-transfected CLL cells (n = 3). Representative FACS plots are presented.
had markedly increased T-cell numbers pre-treatment (CD4 count 3454/ μl, CD8 count 12442/μl); PD-1 expression on CD4+ cells was 54.4% (the second highest level observed in this cohort), while PD-1 expression on CD8+ cells was 8.6% (in the lower quartile). Similar to previous reports, 40 we saw an increase in IgA at 12 months (median 35%, P = 0.015), but no change in IgG (median − 8%, P = 0.2) or IgM (median 5%, P = 0.33). There was a trend (P = 0.09) toward increased incidence of infection in patients who failed to increase IgA levels by 450%. There was no difference in infection in patients according to changes in PD-1 expression with time on CD4+ or CD8+ T cells (data not shown). Of note, 47% of our patient population had 17p deletion. We did not find any difference in PD-1 expression levels on CD4+ and CD8+ T cells in patients with or without this mutation (P = 0.6, P = 0.7, respectively), or in PD-L1 expression on CLL cells in these two groups (P = 0.9).
DISCUSSION
Besides its direct inhibitory effect on BTK signaling, ibrutinib inhibits other tyrosine kinases, 26 including ITK, an essential enzyme in Th2 cells, 41 and thus can shift the balance of T-cell responses toward the more therapeutically favorable Th1 response. This property is reflected by the reduced infectionrelated morbidity in animal models 41 and in patients treated with ibrutinib as shown here and by others. 17, 40 Here we report on the novel observation that ibrutinib exerts additional immunomodulatory effects in CLL through inhibition of B10 function in CLL and by downregulating the expression of two immune checkpoint molecules, PD-1 and its ligand PD-L1. PD-L1 expression by CLL cells enables them to deliver an inhibitory signal to PD-1-positive T cells that actively suppresses T-cell function. [42] [43] [44] In this analysis, treatment with ibrutinib induced significant and selective downregulation of the PD-1/PD-L1 immunosuppressive axis both in vitro and in vivo, with no apparent effect on other recognized inhibitory molecules, including ICOS, 2B4, CD160, OX40, TIM-3 and CTLA-4. In contrast, chlorambucil therapy in patients with CLL had no apparent effect on the expression levels of PD-L1, suggesting that this phenomenon is due to a specific effect of ibrutinib, rather than simply due to non-specific disease debulking. To account for this specific effect on PD-1/PD-L1 signaling, we postulated a STAT3-mediated mechanism. STAT3 is constitutively phosphorylated on serine-727 residues in CLL cells and represents a key pathway involved in the growth and survival of these cells, 23, 27, 45 In addition to its direct role in promoting tumorigenesis, STAT3 plays a significant role in subversion of host immune responses and is responsible for the accumulation and the activation of immunosuppressive cells, such as regulatory T cells, regulatory B cells (Bregs), 8, 9 Th17 cells and myeloid-derived suppressor cells. 46, 47 In this study, we observed a significant reduction in the levels of p-S727-STAT3 in patientderived CLL cells after treatment with ibrutinib both in vivo and in vitro. These findings, together with reports of STAT3 control of PD-L1 expression in T-cell lymphoma and acute myeloid leukemia 30, 47 as well as in tolerogenic antigen-presenting cells, 25, 31 led us to conclude that inhibition of p-STAT3 by ibrutinib allows this agent to block the PD-1/PD-L1 pathway, enhancing the T-cell response in CLL. Indeed, STAT3-shRNA knockdown resulted in significant downregulation of PD-L1 in GFP+CD19+CD5+ CLL cells. Additionally, we demonstrated that BTK knockout can downregulate the constitutive levels of p-S727-STAT3, and abrogate CD40L-induced S727-STAT3 phosphorylation, indicating that BTK inactivation by ibrutinib can mediate a reduction in p-S727-STAT3. Since BTK possesses tyrosine kinase activity, it is unlikely that it can directly phosphorylate the 727 serine residue on STAT3. Instead, it is likely to exert this effect indirectly, possibly through activation of serine kinases such as PKC, AKT/mTOR or p38MAPK. 20, 48, 49 Additional studies are required to determine the exact kinases involved in the phosphorylation of S727-STAT3 in CLL.
We also noted a high expression of PD-1 on the surface of T cells and CLL cells, which was significantly reduced after treatment with ibrutinib. This effect was previously reported with ibrutinib 50 and lenalidomide therapy. 12 We did not find an influence of STAT3 knockdown on PD-1 expression in T cells (Supplementary Figure S8) , suggesting involvement of other mechanisms in this process. Although ibrutinib therapy consistently reduced mean absolute numbers and proportion of PD-1+ T cells, it did not completely abrogate PD-1 expression on T cells. Using a system that allows PD-1 expression to be modulated in otherwise identical cells, Wei et al. 51 showed a direct inverse correlation between the level of PD-1 expression and the ability of T cells to flux Ca 2+ , a pivotal signaling event that controls effector T-cell functions. Thus, we suggest that even partial reductions in PD-1 expression, as seen with ibrutinib therapy, may be adequate to reverse T-cell dysfunction, although this interpretation might be tempered by the likely contributions of other negative regulatory molecules, such as CTLA-4 or TIM-3, that are not suppressed by ibrutinib. PD-1 was also expressed at high levels on CLL cells. PD-1 expression on CLL has been reported by others; 7 however, the significance of this observation remains unknown. A recent study reported an important role for PD-1 in promoting melanoma cell growth. 29 It is therefore possible that PD-1 overexpression on CLL cells may also contribute to their survival.
Recent studies in the TCL1-transgenic mouse model of CLL [52] [53] [54] and patients with CLL [8] [9] [10] 55, 56 report increased frequencies of IL-10-competent B cells with immunosuppressive properties. These cells share several phenotypic markers and functional characteristics with the recently described regulatory B10 cells. [8] [9] [10] 55, 56 Thus, the capacity of CLL cells to produce IL-10 in response to external stimuli may contribute to the immunosuppression observed in patients. We provide support for this hypothesis by demonstrating reduced IL-10 production during ibrutinib treatment of CLL cells, both in vitro and in vivo, that was linked to suppression of STAT3 phosphorylation. We conclude that, in addition to its inhibition of a survival pathway required by BTK-expressing lymphoid cancers, ibrutinib exerts its potentiating effect on immune responses through inhibition of the B10 function of CLL cells and suppression of the PD-1/PD-L1 pathway, both mediated by p-STAT3. Larger patient populations and longitudinal studies are needed to determine whether the specific immunomodulatory effects of ibrutinib will correlate with treatment response and infection risk. Ongoing studies of ibrutinib in combination with checkpoint inhibitors, especially those targeting checkpoint molecules not modulated by ibrutinib such as CTLA-4, will also be of interest.
